Wilding J - Search Results

1

Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events.

Lingvay I, Hansen T, Macura S, Marre M, Nauck MA, de la Rosa R, Woo V, Yildirim E, Wilding J. Lingvay I, et al. Among authors: wilding j. BMJ Open Diabetes Res Care. 2020 Oct;8(2):e001706. doi: 10.1136/bmjdrc-2020-001706. BMJ Open Diabetes Res Care. 2020. PMID: 33115821 Free PMC article.

2

A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment.

Wilding JP, Norwood P, T'joen C, Bastien A, List JF, Fiedorek FT. Wilding JP, et al. Diabetes Care. 2009 Sep;32(9):1656-62. doi: 10.2337/dc09-0517. Epub 2009 Jun 15. Diabetes Care. 2009. PMID: 19528367 Free PMC article. Clinical Trial.

3

Glucagon-like peptide-1 analogues for type 2 diabetes.

Wilding JP, Hardy K. Wilding JP, et al. BMJ. 2011 Feb 16;342:d410. doi: 10.1136/bmj.d410. BMJ. 2011. PMID: 21325387 No abstract available.

4

Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial.

Wilding JP, Woo V, Soler NG, Pahor A, Sugg J, Rohwedder K, Parikh S; Dapagliflozin 006 Study Group. Wilding JP, et al. Ann Intern Med. 2012 Mar 20;156(6):405-15. doi: 10.7326/0003-4819-156-6-201203200-00003. Ann Intern Med. 2012. PMID: 22431673 Free article. Clinical Trial.

5

Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets.

DeVries JH, Bain SC, Rodbard HW, Seufert J, D'Alessio D, Thomsen AB, Zychma M, Rosenstock J; Liraglutide-Detemir Study Group. DeVries JH, et al. Diabetes Care. 2012 Jul;35(7):1446-54. doi: 10.2337/dc11-1928. Epub 2012 May 14. Diabetes Care. 2012. PMID: 22584132 Free PMC article. Clinical Trial.

6

[Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin].

Wilding JP, Woo V, Soler NG, Pahor A, Sugg J, Rohwedder K, Parikh S; Studiengruppe Dapagliflozin 006. Wilding JP, et al. Dtsch Med Wochenschr. 2013 Apr;138 Suppl 1:S27-38. doi: 10.1055/s-0032-1305284. Epub 2013 Mar 25. Dtsch Med Wochenschr. 2013. PMID: 23529568 Clinical Trial. German.

7

Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years.

Wilding JP, Woo V, Rohwedder K, Sugg J, Parikh S; Dapagliflozin 006 Study Group. Wilding JP, et al. Diabetes Obes Metab. 2014 Feb;16(2):124-36. doi: 10.1111/dom.12187. Epub 2013 Aug 29. Diabetes Obes Metab. 2014. PMID: 23911013 Clinical Trial.

8

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.

Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DC, le Roux CW, Violante Ortiz R, Jensen CB, Wilding JP; SCALE Obesity and Prediabetes NN8022-1839 Study Group. Pi-Sunyer X, et al. N Engl J Med. 2015 Jul 2;373(1):11-22. doi: 10.1056/NEJMoa1411892. N Engl J Med. 2015. PMID: 26132939 Free article. Clinical Trial.

9

Exposure-response analyses of liraglutide 3.0 mg for weight management.

Wilding JP, Overgaard RV, Jacobsen LV, Jensen CB, le Roux CW. Wilding JP, et al. Diabetes Obes Metab. 2016 May;18(5):491-9. doi: 10.1111/dom.12639. Epub 2016 Mar 1. Diabetes Obes Metab. 2016. PMID: 26833744 Free PMC article. Clinical Trial.

10

Positioning SGLT2 Inhibitors/Incretin-Based Therapies in the Treatment Algorithm.

Wilding JP, Rajeev SP, DeFronzo RA. Wilding JP, et al. Diabetes Care. 2016 Aug;39 Suppl 2:S154-64. doi: 10.2337/dcS15-3005. Diabetes Care. 2016. PMID: 27440828 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

461 results

Search Page

Filters